{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:25:48Z","timestamp":1778052348228,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.humpath.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:16:13Z","timestamp":1679444173000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement\u2014A 10-case study and literature review"],"prefix":"10.1016","volume":"136","author":[{"given":"Ling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hammad","family":"Tashkandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Fernandez-Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vergara-Lluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinming","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Moscinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seongseok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanyi M.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2023.03.002_bib1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.humpath.2008.02.004","article-title":"The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms","volume":"39","author":"Smith","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2023.03.002_bib2","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2023.03.002_bib3","series-title":"WHO classification of Tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.humpath.2023.03.002_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cancergen.2020.03.001","article-title":"Evidence-based review of genomic aberrations in B-lymphoblastic leukemia\/lymphoma: report from the cancer genomics consortium working group for lymphoblastic leukemia","volume":"243","author":"Akkari","year":"2020","journal-title":"Cancer Genet"},{"key":"10.1016\/j.humpath.2023.03.002_bib5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.03.002_bib6","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2023.03.002_bib7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health organization classification of haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2023.03.002_bib8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.03.002_bib9","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2023.03.002_bib10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41379-021-00817-7","article-title":"Myeloid\/lymphoid neoplasms with FLT3 rearrangement","volume":"34","author":"Tang","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2023.03.002_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","article-title":"Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2","volume":"155","author":"Pozdnyakova","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2023.03.002_bib12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.humpath.2023.03.002_bib13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.leu.2404104","article-title":"A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma","volume":"20","author":"Adelaide","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2023.03.002_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-013-1695-3","article-title":"Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1","volume":"92","author":"Patterer","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.humpath.2023.03.002_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5212","article-title":"Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia","volume":"10","author":"Rizzuto","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.humpath.2023.03.002_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41379-018-0165-9","article-title":"Hematopoietic neoplasms with 9p24\/JAK2 rearrangement: a multicenter study","volume":"32","author":"Tang","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2023.03.002_bib17","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.03.002_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.942053","article-title":"JAK2 alterations in\u00a0acute lymphoblastic leukemia: molecular insights for superior\u00a0precision medicine strategies","volume":"10","author":"Downes","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.humpath.2023.03.002_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/leu.2008.306","article-title":"Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia","volume":"23","author":"Nebral","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2023.03.002_bib20","doi-asserted-by":"crossref","first-page":"89923","DOI":"10.18632\/oncotarget.21027","article-title":"JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Steeghs","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2023.03.002_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2023.03.002_bib22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/gcc.20585","article-title":"Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia","volume":"47","author":"Poitras","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.humpath.2023.03.002_bib23","article-title":"Identification of STRBP as a novel JAK2 fusion partner gene in a young adult with Philadelphia chromosome-like B-lymphoblastic leukemia","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2023.03.002_bib24","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3324\/haematol.2018.192088","article-title":"Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure","volume":"103","author":"Ding","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2023.03.002_bib25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/bjh.17910","article-title":"Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia","volume":"196","author":"Downes","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2023.03.002_bib26","doi-asserted-by":"crossref","first-page":"e1110","DOI":"10.1002\/mgg3.1110","article-title":"Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib","volume":"8","author":"Chen","year":"2020","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.humpath.2023.03.002_bib27","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.mayocp.2019.04.030","article-title":"Identification of a novel ZBTB20-JAK2 fusion by mate-pair sequencing in a young adult with B-lymphoblastic leukemia\/lymphoma","volume":"94","author":"Peterson","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.humpath.2023.03.002_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/2050-7771-1-31","article-title":"A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27","volume":"1","author":"Tirado","year":"2013","journal-title":"Biomark Res"},{"key":"10.1016\/j.humpath.2023.03.002_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/gcc.22251","article-title":"Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21)","volume":"54","author":"Kawamura","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.humpath.2023.03.002_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/gcc.22995","volume":"61","author":"Chen","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.humpath.2023.03.002_bib31","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.03.002_bib32","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1093\/oncolo\/oyac072","article-title":"PCM1-JAK2 fusion tyrosine kinase gene-related neoplasia: a systematic\u00a0review of the clinical literature","volume":"27","author":"Kaplan","year":"2022","journal-title":"Oncol"},{"key":"10.1016\/j.humpath.2023.03.002_bib33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3324\/haematol.2012.067959","article-title":"Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2023.03.002_bib34","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.03.002_bib35","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/bjh.17340","article-title":"Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene","volume":"192","author":"Wouters","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2023.03.002_bib36","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.bbmt.2019.08.010","article-title":"Hematopoietic cell transplant consideration for Philadelphia chromosome-like acute lymphoblastic leukemia patients","volume":"26","author":"El Fakih","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.humpath.2023.03.002_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101242","article-title":"Have any strategies in Ph-like ALL been shown to be effective?","volume":"34","author":"Aldoss","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.humpath.2023.03.002_bib38","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.leukres.2010.05.031","article-title":"Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia","volume":"34","author":"Tirado","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.humpath.2023.03.002_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032451","article-title":"Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase","volume":"7","author":"Cuesta-Dominguez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2023.03.002_bib40","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1182\/blood-2009-07-234229","article-title":"Wide diversity of PAX5 alterations in B-ALL: a groupe francophone de Cytogenetique hematologique study","volume":"115","author":"Coyaud","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.03.002_bib41","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00277-012-1431-4","article-title":"Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia","volume":"91","author":"Zhou","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.humpath.2023.03.002_bib42","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.leu.2400785","article-title":"Chromosome abnormalities of the short arm of chromosome 12 in hematopoietic malignancies: a report including three novel translocations involving the TEL\/ETV6 gene","volume":"11","author":"Berger","year":"1997","journal-title":"Leukemia"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817723000515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817723000515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:41:02Z","timestamp":1758645662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817723000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":42,"alternative-id":["S0046817723000515"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2023.03.002","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement\u2014A 10-case study and literature review","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}